Showcases

Chairing the European Network to Advance Best practices and Technology on Medication Adherence (ENABLE)

In 2020, MAECON was awarded a 4-year grant from the European Commission to set up and chair a COST Action on medication adherence. This European Network to Advance Best practices and Technology on Medication Adherence (ENABLE) currently involves a network of 40 countries across Europe. ENABLE aims to 1) raise awareness of adherence enhancing solutions, 2) foster and extend multidisciplinary knowledge on medication adherence at patient, treatment and system levels, 3) accelerate translation of this knowledge from producers to useful clinical application and 4) work collaboratively towards economically viable policy and implementation of adherence enhancing technology across different European healthcare systems. Research focuses on cross-country comparisons of best practices regarding medication adherence management, identification and assessment of novel technologies and exploration of implementation and reimbursement pathways of adherence enhancing technologies. Outreach activities include the organization of international stakeholder meetings, conferences and symposia, training schools and a fellowship program.

For more information see www.enableadherence.eu and https://www.cost.eu/actions/ca19132/

Funding: COST Action CA19132 “ENABLE,” supported by the COST (European Cooperation in Science and Technology)

Link to publications:
Van Boven JF, et al. European Network to Advance Best Practices and Technology on Medication Adherence: Mission Statement. Frontiers Pharmacol 2021

Kardas P, et al. Disparities in European healthcare system approaches to maintaining continuity of medication for non-communicable diseases during the COVID-19 outbreak. Lancet Reg Health Eur 2021

Agh T, et al. A cross-sectional survey on medication management for noncommunicable diseases in Europe during the second wave of the COVID-19 pandemic. Front Pharmacol 2021

Kardas P, et al. Reimbursed medication adherence enhancing interventions in 12 european countries: Current state of the art and future challenges. Frontiers Pharmacol 2022

Are you interested in one of our services?